Colorectal cancer—global burden, trends, and geographical variations

Douaiher, Jeffrey; Ravipati, Advaitaa; Grams, Benjamin; Chowdhury, Shantanu; Alatise, Olusegun Isaac; Are, Chandrakanth

doi:10.1002/jso.24578

Cited by 213 publications

(167 citation statements)

References 49 publications

(64 reference statements)

Supporting

Mentioning

144

Contrasting

Unclassified

Order By: Relevance

“…Colorectal cancer (CRC) is the third most common malignancy and one of the leading causes of cancer-related deaths worldwide (1)(2)(3). The global burden of CRC is increasing and is likely to persist until the year 2035 and beyond (4). With the introduction of CRC screening, more and more patients benefit from the early detection of precancerous lesions.…”

Section: Introductionmentioning

confidence: 99%

β‑arrestin2 promotes 5‑FU‑induced apoptosis via the NF‑κB pathway in colorectal cancer

Ren

Wang

et al. 2018

Oncol Rep

View full text Add to dashboard Cite

It has been demonstrated that β‑arrestin2 is involved in the initiation and development of many types of cancers. However, its role in colorectal cancer (CRC) remains poorly understood. The present study investigated the role of β‑arrestin2 in CRC using CRC patient tissues as well as the LoVo and HCT116 CRC cell lines. Briefly, significantly higher expression of β‑arrestin2 was observed in CRC tissues compared with normal colon tissues. In addition, the downregulation of β‑arrestin2 reduced 5‑FU‑induced apoptosis in the LoVo cells, while the overexpression of β‑arrestin2 increased the apoptosis of HCT116 cells in vitro. Furthermore, the downregulation of β‑arrestin2 reduced the expression of the pro‑apoptotic proteins cleaved‑caspase‑3 and Bax, and increased the expression of the anti‑apoptotic protein Bcl‑2 after 5‑FU treatment. In addition, the expression of p‑p65 was increased after the β‑arrestin2 downregulation and was decreased after the β‑arrestin2 overexpression. However, β‑arrestin2 downregulation had no effect on the proliferation, migration and invasion capacity of the LoVo cells. In conclusion, these results indicated that β‑arrestin2 promoted 5‑FU‑induced CRC cell apoptosis via the NF‑κB pathway and may be used as a prognosis marker for CRC.

show abstract

Section: Introductionmentioning

confidence: 99%

β‑arrestin2 promotes 5‑FU‑induced apoptosis via the NF‑κB pathway in colorectal cancer

Ren

Wang

et al. 2018

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…Colorectal carcinoma (CRC) is the third leading cause of cancer-associated mortalities worldwide (13). Despite advances in CRC diagnosis and treatment, 142,820 new CRC cases are diagnosed each year (14).…”

Section: Introductionmentioning

confidence: 99%

Low-dose paclitaxel downregulates MYC proto-oncogene bHLH transcription factor expression in colorectal carcinoma cells

Zhu

et al. 2017

Oncol Lett

View full text Add to dashboard Cite

Abstract. Paclitaxel (PTX) has been commonly used to treat multiple types of tumor. Its anticancer mechanism differs based on different PTX concentrations and types of tumor cell. In the present study, MTT assays of HCT116 and LOVO cells treated with PTX revealed the chemosensitivity of the cell lines for different PTX concentrations. The half-maximal inhibitory concentration values of PTX for these cells were 2.46 and 2.24 nM, respectively. Cell morphology observation revealed that both cell lines exhibited rounded, wrinkled and damaged morphologies with increasing concentrations of PTX. Fluorescence-activated cell sorting analysis indicated that 1 nM PTX increased the proportion of cells in sub-G 1 phases and decreased the proportion of cells in G 0 /G 1 phases, whereas the proportions of cells in S and G 2 /M phases only slightly changed for both cell lines. Western blot analysis indicated that the total/nuclear protein expression of MYC proto-oncogene bHLH transcription factor (c-Myc) and phosphorylated (P)-c-Myc decreased in HCT116 cells in a dose-dependent manner, whereas the nuclear protein expression of P-c-Myc increased in LOVO cells in a dose-dependent manner. These results suggest that low-dose PTX downregulates c-Myc and P-c-Myc expression, subsequently inhibiting the cell cycle at G

show abstract

“…Because of economic development and changes in people’s lifestyle, the incidence of CRC is much higher than before [3]. However, in recent years, the rising morbidity rate of CRC has slowed down [4]. However, because of its subclinical manifestations and its characteristic poor prognosis, CRC has a substantial negative impact on human health.…”

Section: Introductionmentioning

confidence: 99%

LncRna CPS1-IT1 Suppresses Cell Proliferation, Invasion and Metastasis in Colorectal Cancer

Zhang¹,

Yuan²,

Song³

et al. 2017

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Increasing evidence demonstrates that long non-coding RNAs (lncRNAs) regulate diverse cellular processes and cancer progression. Whether lncRNAs play any functional role in colorectal carcinoma (CRC) remains largely unknown. The aim of this study was to investigate the role of lncRNA CPS1 intronic transcript 1 (CPS1-IT1) in CRC. Methods: Expression of CPS1-IT1 was initially assessed in human CRC tissues and in a series of CRC cell lines. The correlations between CPS1-IT1 levels and survival outcomes were analyzed to elucidate the clinical significance of CPS1-IT1 in CRC. The underlying mechanisms of CPS1-IT1 in CRC were analyzed through in vitro and in vivo functional assays. Results: Expression of CPS1-IT1 was significantly decreased in CRC tissues and cell lines, and patients with low CPS1-IT1 expression had poor survival outcomes. The results of in vitro assays revealed that CPS1-IT1 significantly reduced cell proliferation, migration and invasion capacities and accelerated cell apoptosis, thereby suppressing epithelial-mesenchymal transition (EMT). An in vivo animal model also demonstrated the tumor-suppressive role of CPS1-IT1. Conclusion: In this study, we found that CPS1-IT1 has a tumor-suppressive role in CRC. Our data suggest that CPS1-IT1 could be used as a new prognostic biomarker and therapeutic target for CRC.

show abstract

Colorectal cancer—global burden, trends, and geographical variations

Abstract: The results of our study demonstrate a rising global burden of CRC with some unique variations. Knowledge of this data can increase awareness and help strategic targeting of efforts and resources.

Cited by 213 publications

References 49 publications

β‑arrestin2 promotes 5‑FU‑induced apoptosis via the NF‑κB pathway in colorectal cancer

β‑arrestin2 promotes 5‑FU‑induced apoptosis via the NF‑κB pathway in colorectal cancer

Low-dose paclitaxel downregulates MYC proto-oncogene bHLH transcription factor expression in colorectal carcinoma cells

LncRna CPS1-IT1 Suppresses Cell Proliferation, Invasion and Metastasis in Colorectal Cancer

Contact Info

Product

Resources

About